The section of Pharmaceutical/Medicinal Chemistry is specialised in structure-activity-related syntheses and the analysis of pharmaceutical ingredients. Syntheses of heterocyclic ring systems are of particular importance.

The actual research is focused on

Group JProf. Dr. Hansen

  • Rational design and diversity-oriented synthesis of isoform-selective histone deacetylase (HDAC) inhibitors
  • Development of parasite-selective antiplasmodial HDAC inhibitors
  • Design and synthesis multi-target drugs
  • Development of novel peptidomimetic α-helix mimetics to modulate protein-protein interactions

Group Dr. Burda-Daghish

  • Green redox chemistry employing enzyme reaction
  • Biocascade reaction and bioprocess development
  • Development of new methods for the detection of protein-binding fragments via dynamic fragment ligation

Group Prof. Dr. Briel

  • Syntheses of annulated heterocycles as inhibitors of PDE 2A and 10A
  • Syntheses of quinazoline derivatives as Adenosine A3 Receptor Antagonists
  • Development of tricyclic PDE2A-Inhibitors and their use as PET-Radiotracer

To top

Former fields of research

    • Synthesis of thieno[2,3-c]pyrazoles having antiulcerative activity
    • Synthesis of heterocyclic thioethers with potentially immunomodulating effects
    • Synthesis of - linked via a heteroatom - heterobicycles and hetero-carbocycles with inhibitory effect on the cellular uptake of triiodothyronine
    • Synthesis and synthetic potential of monocyclic 6-imino-1,3-thiazines
    • Synthesis of 2-amino-5-(het)-arylthiophenes and links from cimetidine type as glutamate antagonists
    • Synthesis of pyrazolopyrimidines as adenosine A2A antagonists
    • Synthesis and conversion reactions of thieno[2,3-d] pyrimidines and thieno [2,3-d]-[1,3]oxazines as inhibitors of the human leukocyte elastase
    • Studies on the synthesis of benzylated and monoglucosidic flavonoids as potential inhibitors of protein kinases
    • Synthesis and structure-activity optimization of diaryl thiazolo[5,4-c]pyrimidines as adenosine A3A antagonists
    • Investigations on subtype-specific GABAA ligands
    • Development and evaluation of novel high-affinity fluorescence probes and small molecule inhibitors für sialyltransferases
      last modified: 13.03.2017